AstraZeneca Reaffirms 2025 Guidance: Expects High Single-Digit Revenue Growth, Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate

Benzinga
2025/07/29

Guidance AstraZeneca reiterates its Total Revenue and Core EPS guidance for FY 2025 at CER, based on the average foreign exchange rates through 2024.  

Total Revenue is expected to increase by a high single-digit percentage

Core EPS is expected to increase by a low double-digit percentage  

The Core Tax rate is expected to be between 18-22% 

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10